BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
Trial will be first Phase 3 disease modifying anti-inflammatory insulin sensitizer therapy in Alzheimer’s disease SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) — BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “ Rationale for an Anti-inflammatory …